A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

Exclusion Criteria

• •Diagnosis of significant respiratory disease other than COPD
• •Comorbid conditions that may interfere with the evaluation of an investigational medical product
• •Known sensitivity or allergy to azithromycin
• •A COPD exacerbation and or pneumonia within 4 weeks prior to Visit 1
• •Use of systemic corticosteroids within 4 weeks (oral or intravenous) or within 12 weeks (intramuscular IM) prior to screening Visit 1
• •MRI is contraindicated
• •Any known arrhythmia, bradycardia or severe cardiac insufficiency
• •Participant can not hold breath for 15 seconds
• •Participant does not fit in the ¹²⁹XE vest coil used for MRI
• •Pregnant, lactating, or intending to become pregnant during the study or within 4 weeks after the last dose of the investigational medical product
• •History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, or have an impact on the study results
• •For participants in Cohort A: Known significant hearing impairment as indicated by a score of ≥ 26 on the Hearing Handicap Inventory in the Elderly-Screening Questionnaire or as determined by the investigator
• •History of Clostridium difficile (C. difficile) diarrhea Clinically significant ECG changes, which in the opinion of investigator warrants further investigation or with a QTc interval \> 450 ms